<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Armodafinil: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Armodafinil: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Armodafinil: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11783" href="/d/html/11783.html" rel="external">see "Armodafinil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F5263022"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nuvigil</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F5263025"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Central Nervous System Stimulant</li></ul></div>
<div class="block doa drugH1Div" id="F5263062"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8711007-1017-4637-a97c-593e06f5423f">Narcolepsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy:</b>
<b>Oral:</b> 150 to 250 mg once daily in the morning.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9033f88e-182a-4ae6-b4b5-c8a283baf192">Obstructive sleep apnea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obstructive sleep apnea: Oral:</b> 150 to 250 mg once daily in the morning; doses &gt;150 mg/day have not been shown to have an increased benefit.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="44cd7219-6c83-4971-85c3-630e56dd368f">Shift-work disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Shift-work disorder:</b>
<b>Oral:</b> 150 mg given once daily ~1 hour prior to work shift.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990601"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987358"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate hepatic impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hepatic impairment: The manufacturer recommends a reduced dose due to decreased clearance and increased steady-state concentration of modafinil in this patient population.</p></div>
<div class="block doe drugH1Div" id="F5263063"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Consider lower initial dosage.</p></div>
<div class="block adr drugH1Div" id="F5263035"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (14% to 23%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased heart rate (1%), palpitations (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (1%), hyperhidrosis (1%), skin rash (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (1%), constipation (1%), decreased appetite (1%), diarrhea (4%), dyspepsia (2%), loose stools (1%), nausea (6% to 9%), upper abdominal pain (2%), vomiting (1%), xerostomia (2% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Seasonal allergy (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (1%), anxiety (4%), depressed mood (1%), depression (1% to 3%), dizziness (5%), fatigue (2%), insomnia (4% to 6%), lack of concentration (1%), migraine (1%), nervousness (1%), pain (1%), paresthesia (1%), tremor (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1%), flu-like symptoms (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms, multi-organ hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypouricemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Irritability</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin changes (including blistering, sores, ulceration), Stevens-Johnson syndrome (Holfinger 2018), toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oral mucosa changes (including blistering, sores, ulceration)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, psychiatric signs and symptoms (including aggressive behavior, delusion, hallucination, mania), suicidal ideation</p></div>
<div class="block coi drugH1Div" id="F5263031"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to armodafinil, modafinil, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F5263032"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May impair the ability to engage in potentially hazardous activities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic effects (severe): Serious and life-threatening rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. In modafinil clinical trials, rashes were more likely to occur in children; serious, postmarketing reactions have occurred with modafinil and armodafinil in adults and children. Most cases have been reported within the first 8 weeks of initiating therapy; however, rare cases have occurred after prolonged therapy. No risk factors have been identified to predict occurrence or severity of these reactions. Patients should be advised to discontinue use at first sign of rash, skin or mouth sores or blistering or ulceration (unless the rash is clearly not drug-related).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Rare cases of drug reaction with eosinophilia and system symptoms (DRESS), also known as multiorgan hypersensitivity, and cases of angioedema and anaphylactoid reactions have been reported. Signs and symptoms of DRESS are diverse. Patients typically present with fever and rash associated with other organ system involvement. Patients should be advised to discontinue therapy and promptly report any signs or symptoms related to these adverse effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use is not recommended in patients with a history of left ventricular hypertrophy or patients with mitral valve prolapse who have developed mitral valve prolapse syndrome with previous CNS stimulant use. Patients with these conditions may also experience chest pain, palpitations, dyspnea, and transient ischemic T-wave changes on ECG. Due to limited experience use caution in patients with history of myocardial infarction (MI) or angina. Increased blood pressure monitoring may be required, and new or additional antihypertensive therapy may be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reduction is recommended with severe dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric disorders: Use caution in patients with a history of psychosis, depression, or mania. Armodafinil has been shown to worsen the symptoms of these diseases (eg, mania, hallucinations, suicidal thoughts). Discontinue therapy if psychiatric symptoms develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep disorders: Appropriate use: For use following complete evaluation of sleepiness and in conjunction with other standard treatments (eg, CPAP). The degree of sleepiness should be reassessed frequently; some patients may not return to a normal level of wakefulness. Patients with excessive sleepiness should be advised to avoid driving or any other potentially dangerous activity. Use &gt;12 weeks has not been studied; patient should be reevaluated to determine effectiveness if use exceeds 12 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tourette syndrome/tics: Use with caution in patients with Tourette syndrome and other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation (AACAP [Murphy 2013]; Pliszka 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use reduced doses in older adults; concentrations of armodafinil are significantly higher in patients &gt;65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse potential: Use with caution in patients with a history of substance use disorder; potential for drug dependency exists.</p></div>
<div class="block foc drugH1Div" id="F5263071"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nuvigil: 50 mg, 150 mg, 200 mg, 250 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 150 mg, 200 mg, 250 mg</p></div>
<div class="block geq drugH1Div" id="F5263024"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324147"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Armodafinil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $7.26 - $7.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $21.86 - $21.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $21.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $21.86 - $21.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Nuvigil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $14.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $43.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $43.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $43.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block csi drugH1Div" id="F5263020"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block adm drugH1Div" id="F5263067"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">May be administered without regard to food. </p></div>
<div class="block meg drugH1Div" id="F10961085"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F021875s023lbl.pdf%23page%3D24&amp;token=JpW5dQ%2F%2FnIxDCaeU%2FlwQie26ReDbZHn6YwMt%2B04IvudJjbICjyoU%2ByldY7ChkiGMMgFHaItybK8G6k2HitQaQPQGTpd%2BTlMpMS31KjF%2BVzftEd06B%2FwuecV%2F5jDTrq4q&amp;TOPIC_ID=9260" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf#page=24</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F5263026"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy:</b> To improve wakefulness in patients with excessive sleepiness associated with narcolepsy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Obstructive sleep apnea:</b> To improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea (OSA).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: In OSA, armodafinil is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating armodafinil for excessive sleepiness.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Shift-work disorder:</b> To improve wakefulness in patients with excessive sleepiness associated with shift-work disorder.</p></div>
<div class="block cyt drugH1Div" id="F5263043"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C19 (weak); <b>Induces</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F5263042"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May diminish the therapeutic effect of Armodafinil.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Armodafinil may decrease the serum concentration of ARIPiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Armodafinil. Armodafinil may decrease the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Weak) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Armodafinil may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the hypertensive effect of CNS Stimulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Weak) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: CNS Stimulants may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Armodafinil may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Armodafinil may decrease the serum concentration of Lumateperone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a weak CYP2C19 inhibitor. For those stable on mavacamten who are initiating a weak CYP2C19 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Armodafinil may decrease the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Armodafinil may decrease serum concentrations of the active metabolite(s) of RisperiDONE. Armodafinil may decrease the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F5263046"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food delays absorption, but minimal effects on bioavailability. Food may affect the onset and time course of armodafinil. Management: Administer without regard to meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F49095563"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to armodafinil initiation; patients who may become pregnant should avoid armodafinil use or use effective contraception during armodafinil therapy (Ghaffari 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Armodafinil induces cytochrome P450 enzymes, decreasing systemic exposure to drugs metabolized via CYP3A4/5. Efficacy of steroidal contraceptives (including depot and implantable contraceptives) may be decreased; alternate means of effective contraception or the addition of a barrier method should be considered during armodafinil therapy and for 1 month after armodafinil is discontinued. Consult drug interactions database for more detailed information specific to use of armodafinil and contraceptives.</p></div>
<div class="block pri drugH1Div" id="F5263028"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Data collected from the Nuvigil/Provigil pregnancy registry suggest an increased risk of major fetal congenital malformations following in utero exposure to armodafinil. Outcome information is based on 148 pregnancies reported to the registry between February 2010 and February 2019 (modafinil n = 81; armodafinil n = 65; both n = 1). Data collected prospectively for 122 pregnancies (102 live births with known outcomes) indicated a 13% rate of major congenital malformations. When including data from retrospective live births (n = 26), the malformation rate remained the same. No specific pattern of malformations was observed (Kaplan 2021). Intrauterine growth restriction and spontaneous abortion have been reported in association with armodafinil.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to armodafinil is ongoing. Health care providers are encouraged to register pregnant patients or pregnant females may register themselves by calling 1-866-404-4106.</p></div>
<div class="block brc drugH1Div" id="F20547471"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Armodafinil is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breast milk was sampled over 24 hours in a female 19 days postpartum following long-term use of modafinil 250 mg daily. The peak breast milk concentration of armodafinil was 2.4 mcg/mL 2 hours after the maternal dose and decreased to 0.43 mcg/mL prior to the next dose. Her infant was not breastfed (Aurora 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during armodafinil therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F5263069"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs of hypersensitivity (especially rash); BP, heart rate; drug misuse.</p></div>
<div class="block pha drugH1Div" id="F5263049"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The exact mechanism of action of armodafinil is unknown. It is the R-enantiomer of modafinil. Armodafinil binds to the dopamine transporter and inhibits dopamine reuptake, which may result in increased extracellular dopamine levels in the brain. However, it does not appear to be a dopamine receptor agonist and also does not appear to bind to or inhibit the most common receptors or enzymes that are relevant for sleep/wake regulation. </p></div>
<div class="block phk drugH1Div" id="F5263051"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Readily absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 42 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~60% (based on modafinil; primarily albumin)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, multiple pathways, including amine hydrolysis and CYP3A4/5; metabolites include R-modafinil acid and modafinil sulfone</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~15 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 2 hours (fasted)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (based on modafinil: 80% predominantly as metabolites; &lt;10% as unchanged drug) </p></div>
<div class="block phksp drugH1Div" id="F51220447"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Severe chronic renal failure (CrCl ≤20 mL/minute) did not influence the pharmacokinetics of modafinil, but increased exposure to modafinil acid ninefold.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with severe hepatic impairment, clearance of modafinil was decreased by ~60% and the steady-state concentration was doubled.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Systemic exposure of armodafinil was ~15% higher and clearance was ~12% lower in patients greater than 65 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F24057142"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Arnifon | Modialex | Nuvigil</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nuvigil</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Armoda</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Nuvigil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Arvigil Ft | Neoresotyl | Nuvigil</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Neoresotyl | Nuvigil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Armodacure | Armowake</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acronite | Armod | Waklert</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nuvigil</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Nuvigil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Neoresotyl</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nuvigil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Nuvigil</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Nuvigil</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Arnifon</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Alertec.2019.06">
<a name="Alertec.2019.06"></a>Alertec (modafinil) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30518447">
<a name="30518447"></a>Aurora S, Aurora N, Datta P, Rewers-Felkins K, Baker T, Hale TW. Evaluating transfer of modafinil into human milk during lactation: A case report. <i>J Clin Sleep Med</i>. 2018;14(12):2087-2089. doi: 10.5664/jcsm.7546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/armodafinil-drug-information/abstract-text/30518447/pubmed" id="30518447" target="_blank">30518447</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ghaffari N, Robertson PA. Caution in prescribing modafinil and armodafinil to individuals who could become pregnant. <i>JAMA Intern Med.</i> 2021;181(2):277-278. doi:10.1001/jamainternmed.2020.4206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/armodafinil-drug-information/abstract-text/33074296/pubmed" id="33074296" target="_blank">33074296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29734973">
<a name="29734973"></a>Holfinger S, Roy A, Schmidt M. Stevens-Johnson syndrome after armodafinil use. <i>J Clin Sleep Med</i>. 2018;14(5):885-887. doi:10.5664/jcsm.7132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/armodafinil-drug-information/abstract-text/29734973/pubmed" id="29734973" target="_blank">29734973</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kaplan S, Braverman DL, Frishman I, Bartov N. Pregnancy and fetal outcomes following exposure to modafinil and armodafinil during pregnancy. <i>JAMA Intern Med.</i> 2021;181(2):275-277. doi:10.1001/jamainternmed.2020.4009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/armodafinil-drug-information/abstract-text/33074297/pubmed" id="33074297" target="_blank">33074297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24290467">
<a name="24290467"></a>Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/armodafinil-drug-information/abstract-text/24290467/pubmed" id="24290467" target="_blank">24290467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nuvigil.1">
<a name="Nuvigil.1"></a>Nuvigil (armodafinil) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17581453">
<a name="17581453"></a>Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007; 46(7): 894-921.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/armodafinil-drug-information/abstract-text/17581453/pubmed" id="17581453" target="_blank">17581453</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9260 Version 291.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
